Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office

CT Open to Enrollment

Use of Blood, Tumor Tissue, and Tumor Infiltrating Lymphocyte Biospecimens for Immune Cell Profiling and Research

The purpose of this study is to facilitate the consent, collection, and research use of biospecimens and data for profiling of immune cells and research from patients seen by physicians at Weill Cornell Medical College/New York-Presbyterian who are screened for, consented to, and undergo tumor-infiltrating lymphocyte (TIL) cellular therapy for solid tumor malignancies.
   

A Multicentre, Prospective, Open-Label, Uncontrolled Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Atenativ in Patients with Congenital Antithrombin Deficiency Undergoing Surgery Or Delivery

This clinical trial is for adults who have congenital antithrombin deficiency (which is a disorder of blood clotting) and who are scheduled to undergo surgery OR childbirth in the near future.
   

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

 This clinical trial is for adults who have been diagnosed with one of the following relapsed or refractory (R/R) B-cell malignancies: non-germinal center B-cell diffuse large B-cell lymphoma (non-GCB DLBCL), follicular lymphoma (FL), Richter’s Transformation (RT), Waldenstrom macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL).
   

Venetoclax In Combination with ASTX727, an All-Oral TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY- MDS/MPN): a Randomized, Phase 2 trial

This study is being done to evaluate if the combination of ASTX727 and venetoclax works better than ASTX727 alone at decreasing the signs and symptoms of bone marrow cancer, known as myelodysplastic/myeloproliferative neoplasm (MDS/MPN).

We are doing this study because we want to find out if this approach is better or worse than the usual approach for bone marrow cancer called chronic myelomonocytic leukemia (CMML) or a less common form called non-CMML MDS/MPN. The usual approach is defined as care most people get.

Evaluating the prevalence of metabolic dysfunction associated steatotic liver disease (MASLD) during pregnancy and its influence on pregnancy outcomes and postpartum maternal health

The primary objective of the study is to understand how common fatty liver disease, which has a new updated name called Steatotic Liver Disease (SLD) or metabolic dysfunction associated steatotic liver disease (MASLD), is seen in pregnant people and if it affects pregnancy health and outcomes. This study assesses liver health throughout pregnancy and after delivery. 
   

A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy

The purpose of this study is to evaluate the efficacy of adding cusatuzumab to venetoclax plus azacitidine (VAC) compared to venetoclax plus azacitidine (VA) alone for patients with acute myeloid leukemia (AML).

Cusatuzumab is considered investigational which means it has not been approved by the U.S. Food and Drug Administration (FDA). Azacitidine and venetoclax are both FDA-approved.   

Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson's Disease Patients with Motor Complications

This is a randomized clinical research study examining an investigational treatment called CVN424 in patients with Parkinson's Disease (PD).

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease

This phase 3 program is evaluating the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn’s Disease.
   

A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab in Combination With Pola-R-CHP Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

This clinical trial is for adults who have a certain type of cancer called large B-cell lymphoma (LBCL) and have not yet received treatment for it.
   

Serranator OCT: Understanding the Mechanism of Action of Serration Angioplasty by Serranator Versus Conventional Balloon Angioplasty for below-the Knee (BTK) Artery Disease Using Optical Coherence Tomography (OCT)

The purpose of this prospective randomized trial is to evaluate the serration angioplasty effect in below the knee arteries with calcified plaque when the Serranator Serration Angioplasty Balloon is used as compared to a conventional balloon angioplasty.

Conventional balloon angioplasty is a regularly used approach. The Serranator Angioplasty Nalloon is U.S. Food and Drug Administration (FDA) approved and commercially available.